Crossmark Global Holdings Inc. Raises Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Crossmark Global Holdings Inc. lifted its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 16.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,161 shares of the biotechnology company’s stock after purchasing an additional 994 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Sarepta Therapeutics were worth $894,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Innealta Capital LLC purchased a new position in Sarepta Therapeutics in the 2nd quarter worth about $31,000. New Covenant Trust Company N.A. purchased a new position in shares of Sarepta Therapeutics during the first quarter valued at approximately $32,000. Nkcfo LLC purchased a new stake in Sarepta Therapeutics in the second quarter worth approximately $43,000. Riggs Asset Managment Co. Inc. grew its position in Sarepta Therapeutics by 33.3% in the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 75 shares during the period. Finally, UMB Bank n.a. grew its position in Sarepta Therapeutics by 105.9% in the 3rd quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 197 shares during the period. 86.68% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of Sarepta Therapeutics stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the sale, the chief financial officer now owns 33,946 shares of the company’s stock, valued at $4,662,822.56. The trade was a 14.99 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Price Performance

Shares of NASDAQ:SRPT opened at $109.11 on Friday. The firm has a market cap of $10.42 billion, a price-to-earnings ratio of 87.29 and a beta of 0.81. The firm has a fifty day moving average price of $124.21 and a 200 day moving average price of $132.49. Sarepta Therapeutics, Inc. has a fifty-two week low of $78.67 and a fifty-two week high of $173.25. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84.

Analyst Upgrades and Downgrades

SRPT has been the subject of several research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $205.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, November 7th. Raymond James restated an “outperform” rating and set a $150.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, October 10th. Barclays lowered their price objective on shares of Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. UBS Group upped their target price on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a report on Tuesday, September 17th. Finally, William Blair upgraded shares of Sarepta Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. One equities research analyst has rated the stock with a hold rating, twenty-one have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $181.33.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.